TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9706921

Group type: EXPERIMENTAL
Intervention: Drinking group (mandatory oral fluids, approximately 150 mL)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Nondrinking group (no oral fluids)
Number of subjects: 726
Study: 8561443

Group type: EXPERIMENTAL
Intervention: Tildiem 60 mg (240 mg total daily dose in three divided doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bi-Tildiem 120 mg (two daily doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30170304

Group type: EXPERIMENTAL
Intervention: Olive oil (20 g/d for 12 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sunflower oil (20 g/d for 12 weeks)
Number of subjects: 66
Study: 29240854

Group type: EXPERIMENTAL
Intervention: Product containing human fibroblast-derived growth factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25414081

Group type: EXPERIMENTAL
Intervention: Suboptimal instrument placement
Number of subjects: 478
Study: 23406052

Group type: EXPERIMENTAL
Intervention: Sumatriptan-naproxen (Treximet®)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20679180

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg per day for 8 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine (adenosine receptor antagonist)
Number of subjects: 0
Study: 17227688

Group type: EXPERIMENTAL
Intervention: Zoster vaccine potency 58,000 plaque-forming units/dose
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Zoster vaccine potency 207,000 plaque-forming units/dose
Number of subjects: 698
Study: 16271341

Group type: EXPERIMENTAL
Intervention: Children with a positive history of constipation in parents
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Children with anorectal disorders
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Children aged 1-2 years
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Children older than 2 years
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Children living in households with more persons and rooms
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Children with painful defecation episodes
Number of subjects: 2680
Study: 12140349

Group type: EXPERIMENTAL
Intervention: Caffeine (500 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 10080053

Group type: EXPERIMENTAL
Intervention: Phenytoin (20 mg/kg loading dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 13
Study: 7589767

Group type: EXPERIMENTAL
Intervention: Diltiazem 200-300 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Captopril 12.5-25 mg twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diltiazem and Captopril
Number of subjects: 100

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 100
Study: 2262955

Group type: EXPERIMENTAL
Intervention: Long-acting penicillin
Number of subjects: 179
Study: 7206848

Group type: EXPERIMENTAL
Intervention: Health screening plus health education
Number of subjects: 165

Group type: COMPARATOR
Intervention: Health screening control
Number of subjects: 165

Group type: COMPARATOR
Intervention: No contact comparison
Number of subjects: 165
Study: 31562798

Group type: EXPERIMENTAL
Intervention: PCI with fluoropolymer‐based cobalt‐chromium everolimus‐eluting stents
Number of subjects: 1905

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1905
Study: 28911925

Group type: EXPERIMENTAL
Intervention: FlexibleMIB
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 312
Study: 25843821

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.25 μg/kg/minute (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.75 μg/kg/minute (group 3)
Number of subjects: 20
Study: 25108752

Group type: EXPERIMENTAL
Intervention: Kinesiotaping with exercise
Number of subjects: 54

Group type: COMPARATOR
Intervention: Manual therapy with exercise
Number of subjects: 54
Study: 22838386

Group type: EXPERIMENTAL
Intervention: Probiotic bacterium Enterococcus faecium NCIMB 10415
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-supplemented)
Number of subjects: 0
Study: 19440896

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral skills training program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) control condition
Number of subjects: 160
Study: 17439512

Group type: EXPERIMENTAL
Intervention: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Group 2 (10 mg rabeprazole + 750 mg amoxicillin + 400 mg clarithromycin twice daily for 7 days)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Group 3 (20 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Group 4 (20 mg rabeprazole + 750 mg amoxicillin + 400 mg clarithromycin twice daily for 7 days)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Clarithromycin-susceptible strains
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Extensive metabolizers
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Poor metabolizers
Number of subjects: 479
Study: 16312924

Group type: EXPERIMENTAL
Intervention: Needling lateral cervical Jiaji group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Traditional Jiaji group
Number of subjects: 72
Study: 12086370

Group type: EXPERIMENTAL
Intervention: Budesonide 256 microg
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Budesonide 128 microg
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 microg
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 9459252

Group type: EXPERIMENTAL
Intervention: lidocaine 2% administered through a 25-gauge needle (lido-25)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: lidocaine 2% mixed with sodium bicarbonate administered through a 25-gauge needle (lido-bicarb-25)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: lidocaine 2% administered through a 30-gauge needle (lido-30)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: lidocaine 2% mixed with sodium bicarbonate administered through a 30-gauge needle (lido-bicarb-30)
Number of subjects: 40

Group type: COMPARATOR
Intervention: lido-bicarb-30
Number of subjects: 40
Study: 7887377

Group type: EXPERIMENTAL
Intervention: c7E3 Fab (IIb/IIIa platelet receptor antagonist)
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study: 2116119

Group type: EXPERIMENTAL
Intervention: Single-lumen catheters
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Double-lumen catheters
Number of subjects: 112
Study: 883331

Group type: EXPERIMENTAL
Intervention: Conservative treatment (partial mastectomy plus axillary dissection plus postoperative radiotherapy)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Additional radiotherapy to supraclavicular and internal mammary node areas
Number of subjects: 302

Group type: COMPARATOR
Intervention: No additional radiotherapy
Number of subjects: 302
Study: 30653423

Group type: EXPERIMENTAL
Intervention: Site-specific therapy based on gene expression profiling
Number of subjects: 130

Group type: COMPARATOR
Intervention: Empirical chemotherapy with paclitaxel and carboplatin (PC)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Predicted more-responsive tumor types
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Predicted less-responsive tumor types
Number of subjects: 130
Study: 30429461

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant fibroblast growth factor-2 (rFGF-2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cigarette smoke exposure
Number of subjects: 6

Group type: COMPARATOR
Intervention: Elastase-induced emphysema model
Number of subjects: 6
Study: 27161105

Group type: EXPERIMENTAL
Intervention: 3 × 300 mg/d WS® 5570
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg/d paroxetine
Number of subjects: 0
Study: 24141008

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control (no UDCA)
Number of subjects: 242
Study: 22360152

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 72
Study: 19410035

Group type: EXPERIMENTAL
Intervention: Glyceryl nitrate (GN) 15 mg/24 hours transdermal patch
Number of subjects: 806

Group type: COMPARATOR
Intervention: Placebo (PL) identical-looking patch
Number of subjects: 806
Study: 17656180

Group type: EXPERIMENTAL
Intervention: CARRA/LNG gel (0.75 mg levonorgestrel)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carraguard (CARRA) gel
Number of subjects: 24
Study: 15945342

Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study: 11874925

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lower-Protein (LP) diet
Number of subjects: 54
Study: 10593346

Group type: EXPERIMENTAL
Intervention: Fenfluramine and phentermine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7760989

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (diazepam, lorazepam) and benzodiazepine-like anxiolytics (alpidem, suriclone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-HT-3 antagonist (ondansetron)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2139523

Group type: EXPERIMENTAL
Intervention: tamoxifen (TAM) (20 mg/die) until progression
Number of subjects: 60

Group type: COMPARATOR
Intervention: tamoxifen (TAM) (20 mg/die for 14 days) then medroxyprogesterone acetate (MPA) (1500 mg/die p.o. for 14 days)
Number of subjects: 60
Study: 6998390

Group type: EXPERIMENTAL
Intervention: Topical cephradine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous cephradine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical and intravenous cephradine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 0
Study: 29626134

Group type: EXPERIMENTAL
Intervention: mTICI 2C
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: mTICI 3
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: mTICI 2C and 3 combined
Number of subjects: 290

Group type: COMPARATOR
Intervention: mTICI 2B
Number of subjects: 290
Study: 26970480

Group type: EXPERIMENTAL
Intervention: VP shunt insertion plus dopamine oral therapy (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: VP shunt alone (group B)
Number of subjects: 30
Study: 25483667

Group type: EXPERIMENTAL
Intervention: ID 9 μg intradermal vaccine
Number of subjects: 80

Group type: COMPARATOR
Intervention: IM 15 μg intramuscular vaccine
Number of subjects: 80
Study: 22300528

Group type: EXPERIMENTAL
Intervention: Infliximab (anti-tumor necrosis factor-alpha)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 20397759

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (n = 37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (n = 38)
Number of subjects: 75
Study: 18701020

Group type: EXPERIMENTAL
Intervention: Diabetes specific formula (Diason low energy: 313.8 kJ/100 ml)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 71
Study: 15806000

Group type: EXPERIMENTAL
Intervention: Intranasal R112 (3 mg/nostril every 4 hours x 2)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Intranasal R112
Number of subjects: 319
Study: 12879672

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 250

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 250
Study: 10382126

Group type: EXPERIMENTAL
Intervention: Clarithromycin, 500 mg bid for 2 weeks plus RBC, 400 mg bid for 4 weeks
Number of subjects: 383

Group type: COMPARATOR
Intervention: Clarithromycin, 500 mg tid for 2 weeks plus RBC, 400 mg bid for 4 weeks
Number of subjects: 383
Study: 8884146

Group type: EXPERIMENTAL
Intervention: Active therapy (600 mg/day of GLA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 2056983

Group type: EXPERIMENTAL
Intervention: Midazolam plus ketamine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Midazolam plus placebo
Number of subjects: 129
Study: 6362471

Group type: EXPERIMENTAL
Intervention: Enteric-coated Conjuvac Timothy tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enteric-coated Whole Timothy pollen tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enteric-coated placebo tablets
Number of subjects: 12
Study: 30971419

Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive-behavioural therapy (TCBT)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Web-delivered cognitive-behavioural therapy (WCBT)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 558
Study: 29797592

Group type: EXPERIMENTAL
Intervention: Eccentric-based injury prevention program (IPP) administered 1 day post-match (MD+1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Eccentric-based injury prevention program (IPP) administered 3 days post-match (MD+3)
Number of subjects: 18
Study: 27064798

Group type: EXPERIMENTAL
Intervention: Bare metal stent post-dilated with a paclitaxel-coated balloon
Number of subjects: 32
Study: 24887897

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 249

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 249
Study: 22808224

Group type: EXPERIMENTAL
Intervention: Bright light (BL: ≈ 4.420 lx)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dim light (DL: ≈ 230 lx)
Number of subjects: 43
Study: 19918047

Group type: EXPERIMENTAL
Intervention: teriparatide 20 microg/day
Number of subjects: 387

Group type: COMPARATOR
Intervention: alendronate 10 mg/day
Number of subjects: 387
Study: 16959916

Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins E, A, and C for 2 months, allopurinol for 15 days, and N-acetylcysteine for 3 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15938591

Group type: EXPERIMENTAL
Intervention: Omeprazole pre-treatment for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alginate tablets alone
Number of subjects: 12
Study: 11984383

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol (IPA) inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard anti-emetic treatment
Number of subjects: 0
Study: 9523400

Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Investigational protocol
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction
Number of subjects: 2200
Study: 8588647

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 2691174

Group type: EXPERIMENTAL
Intervention: Octreotide (SMS 201-995, 50 micrograms subcutaneously)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 4270384

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 0
Study: 31221117

Group type: EXPERIMENTAL
Intervention: Promotora-led intervention
Number of subjects: 620
Study: 29245361

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol-Remifentanil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol-Midazolam-Remifentanil
Number of subjects: 120
Study: 26046967

Group type: EXPERIMENTAL
Intervention: Low-dose rhIGF‐I/rhIGFBP‐3 (30 mg/d)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose rhIGF‐I/rhIGFBP‐3 (60 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 23446019

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (E-PRP) drops for 3 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Balanced saline solution
Number of subjects: 108
Study: 17129461

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline (200 mg/d) twice daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 12581466

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable subscription (one piece per day)
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Control group (no subscription)
Number of subjects: 1493
Study: 11112891

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol combination (FP/Salm Combo) - FP 100 microg plus salmeterol 50 microg twice daily through the Diskus inhaler
Number of subjects: 447

Group type: COMPARATOR
Intervention: Fluticasone propionate plus montelukast (FP + montelukast) - FP 100 microg twice daily plus oral montelukast 10 mg once daily
Number of subjects: 447
Study: 8840374

Group type: EXPERIMENTAL
Intervention: Erythromycin (mean rate 8.9 +/- 3.5 mg/minute, range 3.9-16.7 mg/minute)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control antibiotics (ceftazidime, cefuroxime, cefotaxime, ceftriaxone, or ampicillin-sulbactam)
Number of subjects: 44
Study: 1334524

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 10 mg daily with conjugated equine oestrogens 0.625 mg (CEE)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 10 mg daily with transdermal 17 beta‐oestradiol 0.05 mg (E2‐TTS)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (87 postmenopausal women)
Number of subjects: 124
Study: 6427533

Group type: EXPERIMENTAL
Intervention: Single-dose therapy with trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 10-day multiple-dose therapy with trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both treatment groups (single-dose and multiple-dose)
Number of subjects: 200
Study: 30557693

Group type: EXPERIMENTAL
Intervention: Iron and/or zinc supplementation
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 602
Study: 28072691

Group type: EXPERIMENTAL
Intervention: Clopidogrel 50 mg plus aspirin 100 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg plus aspirin 100 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Aspirin 100 mg
Number of subjects: 200
Study: 25468004

Group type: EXPERIMENTAL
Intervention: Single-session brief intervention with family support (BI-FS)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Single-session brief intervention (BI)
Number of subjects: 169
Study: 23673251

Group type: EXPERIMENTAL
Intervention: Short-term media violence exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21749907

Group type: EXPERIMENTAL
Intervention: Escitalopram (N=16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sertraline (N=14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Escitalopram and Sertraline (combined)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls (N=28)
Number of subjects: 30
Study: 19969212

Group type: EXPERIMENTAL
Intervention: ICRS implantation followed by CXL (Group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXL followed by ICRS implantation (Group 1)
Number of subjects: 0
Study: 17589773

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MM) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron only supplementation
Number of subjects: 0
Study: 15249503

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 459

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents in proximal LAD lesions
Number of subjects: 459

Group type: COMPARATOR
Intervention: Bare-metal stents in proximal LAD lesions
Number of subjects: 459
Study: 11578883

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 2438

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 2438
Study: 9775925

Group type: EXPERIMENTAL
Intervention: Foot Reflexology (FR) for 15 minutes for 5 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Foot/Leg Massage (FM) for 15 minutes for 5 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Talking for 15 minutes for 5 days
Number of subjects: 130
Study: 7848398

Group type: EXPERIMENTAL
Intervention: Argyle tracheal tube
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Portex tracheal tube
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Kendall Curity tracheal tube
Number of subjects: 90
Study: 3071588

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg three times a day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg three times a day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29890864

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg) as part of a multimodal cocktail injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multimodal cocktail injection without morphine (control group)
Number of subjects: 100
Study: 29231438

Group type: EXPERIMENTAL
Intervention: Needle-knife treatment (Fengchi GB 20, infraoccipital ashi point), once every three days for 5 times as one course.
Number of subjects: 366

Group type: COMPARATOR
Intervention: Massage treatment, once every two days for 7 times as one course.
Number of subjects: 366
Study: 25906792

Group type: EXPERIMENTAL
Intervention: Film ending with protagonist's suicide
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Film featuring main character positively coping with crisis
Number of subjects: 95